Newsroom News At Zentiva, we provide health and wellbeing for all generations GTCR Completes Acquisition of Zentiva Chicago, IL; Prague, Czech Republic; April 9, 2026 - GTCR, a leading private equity firm, announced today that it has closed the previously announced acquisition of Zentiva (the “Company”), a leading European generics pharmaceutical company, from Advent, a leading global private equity investor. Newsroom Zentiva is focused on the development, manufacturing and supply of generic, branded specialty and over-the-counter medicines and products, serving more than 100 million people across over 40 countries. The Company is supported by established R&amp;D capabilities and a deep commitment to clinical excellence and product quality across its portfolio.GTCR will partner with Zentiva’s management team, led by Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy, to support the Company’s next phase of growth. GTCR has longstanding relationships with both Mr. Saltofte and Mr. Murphy, both seasoned leaders with proven track records at various healthcare businesses, including at Acino and GE HealthCare.GTCR has a long history of investing in healthcare over the past 45 years, including in the pharmaceutical sector. The firm will support Zentiva’s next phase of growth through continued investment in new product development, portfolio breadth, and geographic reach, with a focus on improving patient access to essential medicines and supporting sustainable healthcare systems.   Etiam malesuada tempus viverra “We are excited to partner with Steffen and the Zentiva team to further the Company’s success,” said Sean Cunningham, Managing Director and Head of Healthcare at GTCR. “As policymakers increasingly prioritize expanding access to essential medicines while ensuring long-term sustainability of healthcare systems, Zentiva plays a critical role in delivering high-quality, cost-effective therapies at scale. Combined with its differentiated geographic footprint and low-cost manufacturing capabilities, Zentiva is well positioned to strengthen its competitive advantage and deliver long-term growth and impact.”Tom Allen, Managing Director at Advent, added, “We are immensely proud of the business Zentiva has become during our partnership — a scaled, growing European generics platform, with a strong competitive footprint, a commitment to quality, and a clear mission to expand access to affordable medicines. We would like to thank Steffen and all the talented Zentiva team members who played a part in the company’s transformation.  We look forward to watching Zentiva go from strength to strength in the years ahead.”GTCR was advised by Barclays Bank PLC, acting through its Investment Bank, and BNP Paribas as lead financial advisors, Morgan Stanley &amp; Co. LLC as a financial advisor, and Kirkland &amp; Ellis LLP as legal advisor.Advent was advised by Goldman Sachs and PJT Partners as lead financial advisors and Freshfields as lead legal advisor. Downloads Press release Press release Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business &amp; Consumer Services, Financial Services &amp; Technology, Healthcare and Technology, Media &amp; Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn. About GTCR Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe and beyond. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents, bonded together by a commitment to the people who depend on our products every day.  Visit us at www.zentiva.com  About Zentiva Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 16 offices across five continents, we oversee more than USD $100 billion in assets under management* and have made 448 investments across 44 countries.Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business &amp; financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans. We bring hands-on operational expertise to enhance and accelerate businesses.As one of the largest privately-owned partnerships, our 655 colleagues leverage the full ecosystem of Advent’s global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals.To learn more, visit our website or connect with us on LinkedIn.*Assets under management (AUM) as of September 30, 2025. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles. About Advent Media Contacts Newsroom

GTCR Completes Acquisition of Zentiva

2026-04-09-gtcr-completes-acquisition-of-zentiva

GTCR to support Zentiva’s next phase of growth, building on its strong foundation of quality, scale and market leadership

Newsroom News At Zentiva, we provide health and wellbeing for all generations Zentiva publishes 2025 Sustainability Report reinforcing commitment to people, partners and the planet.  Newsroom Prague, March 16, 2026 – Zentiva today publishes its 2025 Sustainability Report, presenting another year of progress in public health impact, environmental stewardship and responsible business practices.In 2025, Zentiva demonstrated once again that business growth and environmental responsibility can go hand in hand, cutting emissions by 10 percent across its own operations (Scope 1 &amp; 2 emissions) while increasing net sales and EBITDA.The Science Based Targets initiative (SBTi) validated Zentiva’s near-term and long-term targets - including a 63% reduction of Scope 1, 2 and 3 emissions by 2034, and net zero by 2050.Key achievements in 2025 include:83% of electricity used across Zentiva operations is now from renewable sources – and a full 100% across EU manufacturing sites.The volume of water recycled and reused between 2021 and 2025 almost doubled.47% of waste diverted from disposal – reused, recycled or otherwise repurposed.130,000+ trees planted to assist reforestation and 3.5 million bees adopted as part of Zentiva projects to support biodiversity and be a ‘responsible corporate citizen’.120+ ‘people and community’ projects delivered in Europe and India.  #WeHelpOthersZentiva received a Gold medal from EcoVadis, positioning the Sustainability program in the top 2% of the pharmaceutical industry. We were also pleased to receive a Transparency Award 2025 from EUPD Group for our sustainability reporting and communication. Etiam malesuada tempus viverra As a leading provider and manufacturer of off patent medicines in Europe, Zentiva plays a critical role in ensuring that people across the continent can access the high quality and affordable medicines they depend on every day. Off patent medicines represent roughly 70% of all dispensed medicines, yet only 19% of pharmaceutical spending, making them essential to the affordability and sustainability of public health systems (IQVIA, 2024).Zentiva continues to invest in its manufacturing footprint and sustainability strategy to ensure patients have consistent access to medicines - today and in the future.The Zentiva 2025 Sustainability Report is available at www.zentiva.com/sustainability. 2025 Sustainability Report Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents in over 30 countries, bonded together by a commitment to the people who depend on our products every day. Visit us at www.zentiva.com. About Zentiva For further information or queries please contact: Newsroom

Zentiva publishes 2025 Sustainability Report reinforcing commitment to people, partners and the planet.

2026-03-16-sustainability-report-2025

Newsroom News At Zentiva, we provide health and wellbeing for all generations Zentiva Demands EU‑Level Stop‑the‑Clock on the UWWTD to Protect Medicine Availability Newsroom Prague, 23 February 2026 – Zentiva, a leading European manufacturer of high‑quality and affordable medicines, responds to the decision of the General Court of the European Union concerning the Urban Waste Water Treatment Directive (UWWTD) reiterating that the UWWTD, in its current form, poses a significant risk to the secure supply of essential medicines in Europe.Following the adoption of the Directive, despite major concerns raised by 16 EU Member States, in 2025 Zentiva filed a legal action to request annulment of the Directive to safeguard the secure supply of essential medicines for the patients who depend on them every day.The recent decision clarifies how the Court interprets legal standing under EU law. It concludes that Zentiva and other generic and off patent medicine manufacturers are not considered individually affected, and therefore do not have a direct judicial route to challenge the Directive - even though its impact on the sector and on the medicines we supply across Europe is real and substantial. Importantly, the Court did not assess the substance of the case - including whether the Extended Producer Responsibility (EPR) scheme under the UWWTD is compatible with EU law or whether the cost model is workable, proportionate, or safe for securing the continuity of medicine supply. Etiam malesuada tempus viverra If implemented without correction, the Directive may render many essential medicines economically unsustainable to produce. The result would directly affect patients across all EU Member States, reducing access to affordable treatments and increasing the risk of medicine shortages. Ultimately, patients would pay the price. The Court outcome does not resolve these long standing issues - it leaves the substance of the Directive and its practical impact unaddressed, reinforcing the need for a political and policy‑level correction before full implementation causes harm.The generics industry counts for 70% of all dispensed medicines, and 9 out of 10 critical medicines. If no further measures are taken and the Directive in its current form is transposed into national legislation across 27 countries, it is highly likely to lead to massive shortages. Saltofte further commented: “As the CEO of a European-based company and President of Medicines for Europe, the representation of the off-patent medicine industry, I will not sit back and watch this happen. We will continue to insist on a solution that we must develop together - not in silos, and not without industry. This issue requires all stakeholders at one table to pause the implementation, repair it at EU level, and relaunch it in a workable way across Europe - ensuring clean water without jeopardizing the availability, accessibility, and affordability of healthcare for the people in Europe who depend on these medicines every day.”What needs to happen nextThe Directive has been adopted and is entering national implementation, making political leadership and dialogue more urgent than ever. Zentiva calls for:A pause in the current implementation of the UWWTD at EU level, allowing an inclusive dialogue of EU institutions, Member States, water operators, patients, healthcare systems and industry,Conduct new independent studies, as part of a necessary repair of the Directive, based on sound science, proportionality and real world healthcare economics, to assess the impact on the availability, accessibility and affordability of medicines,A relaunch of the Directive in a workable form that delivers clean water without jeopardising the availability, accessibility and affordability of medicines for patients across Europe.  Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents, bonded together by a commitment to the people who depend on our medicines every day. Visit us at www.zentiva.com  About Zentiva Media contacts:  Newsroom

Zentiva Demands EU‑Level Stop‑the‑Clock on the UWWTD to Protect Medicine Availability

2026-02-23-uwwtd

zentiva

daily

Header

Footer

Default

News

2022-07-08-allergy-day

World Allergy Day

Latest News

GTCR Completes Acquisition of Zentiva

Zentiva publishes 2025 Sustainability Report reinforcing commitment to people, partners and the planet.

Zentiva Demands EU‑Level Stop‑the‑Clock on the UWWTD to Protect Medicine Availability

Explore

Stay tuned

Get in touch